The Integrated Health Care System That Patients Still Cannot See

What if the hardest thing to see in American health care is not the price of care, but who has the power to define what a price means?

A patient may ask a simple question: “How much will this MRI cost?” The answer can change depending on whether the question is typed into a hospital website, asked over the phone, routed through an insurer, or processed by a pharmacy and benefits company. That is not merely a customer service problem. It is evidence that the health care market does not have one price system. It has overlapping systems, each controlled by organizations with different incentives and different access to information.

At the same time, the largest companies increasingly operate across several layers of that system. Insurers own or closely coordinate with pharmacy benefit managers, specialty pharmacies, clinics, and provider organizations. The result is a health care economy that is becoming more vertically connected at the corporate level while remaining profoundly fragmented from the patient’s perspective.

These two developments are usually discussed separately. One is described as consolidation. The other is described as poor price transparency. Together, they reveal a deeper problem: health care is becoming more integrated for institutions and less legible for everyone who depends on it.

The strange paradox of an integrated but unreadable system

In an ordinary market, integration can make a product easier to understand. A company that designs, manufactures, distributes, and sells a product may be able to provide a single price and a consistent customer experience. Health care often works in the opposite direction.

As insurers, pharmacy benefit managers, specialty pharmacies, and providers become linked through ownership, contracts, referrals, data systems, and negotiated arrangements, the patient encounters more layers, not fewer. A single episode of care can involve a hospital, an insurer, a physician group, a laboratory, a pharmacy benefit manager, a specialty pharmacy, and a manufacturer assistance program. Each participant may have a legitimate role. Yet the patient is left trying to infer the total cost from fragments.

This creates what we might call the integration paradox:

The more tightly organizations coordinate behind the scenes, the less obvious it may become who is responsible for the price the patient sees.

Vertical integration is not automatically harmful. It can reduce duplicated work, improve coordination, and make it easier to manage complex treatments. A specialty pharmacy connected to a health plan may help a patient obtain an expensive medicine more quickly. A provider group aligned with an insurer may have stronger incentives to avoid unnecessary hospitalizations.

But integration also changes the location of power. When one corporate family occupies several positions in the chain, it can influence what gets recommended, where it is delivered, which pharmacy fills it, how it is reimbursed, and what information reaches the patient. The key question is not simply whether the system is integrated. It is integrated for whose benefit, and with what visibility?

A patient does not experience vertical integration as an organizational chart. The patient experiences it as a sequence of choices that appear to be independent but may be connected by ownership or financial incentives.

A referral can look like advice. A preferred pharmacy can look like convenience. A benefit design can look like an unavoidable rule. A price estimate can look like a fact. Yet each may be the visible output of a system in which the same enterprise has influence over multiple decisions.

A price is not a number until the system can reproduce it

The hospital pricing evidence exposes a more basic failure than high prices. It shows that the system often cannot provide a stable answer to a straightforward question.

In one examination of hospital estimates for vaginal childbirth, only three of 22 hospitals gave matching estimates when patients requested prices online and by phone. Nine hospitals produced estimates that differed by at least 50 percent. For brain MRIs, the results were better but still troubling: nine of 47 hospitals gave matching online and phone estimates, while 12 gave estimates differing by at least 50 percent.

These discrepancies matter even when no one is acting in bad faith. A price that changes depending on the communication channel is not functioning as a reliable price. It is closer to a provisional story assembled from incomplete data.

The ranges between hospitals were also enormous. Online estimates for vaginal childbirth at highly ranked facilities ranged from zero dollars to $55,221. At safety net hospitals, the range was narrower but still substantial, from $4,361 to $14,377. Such variation may reflect differences in services, insurance status, negotiated rates, complications, or the definition of the episode. But that is precisely the problem. If the system cannot explain the source of the variation in a way that a patient can use, the number is technically available but practically opaque.

This distinction is essential. Disclosure is not the same as transparency. A hospital can publish a large data file and still fail to answer a patient’s question. A number becomes transparent only when it is understandable, relevant to the decision at hand, and reproducible across reasonable ways of asking.

Imagine buying a plane ticket where the displayed fare changed depending on whether you used the airline’s website or called customer service, and where the final amount depended on a hidden relationship among the airline, the airport, the payment processor, and the travel agency. The problem would not be solved by placing a massive spreadsheet online. Travelers would demand a clear itinerary, a total price, and an explanation of the conditions that could change it.

Health care deserves the same standard, even though its services are more complex.

The hidden connection: integration makes opacity more consequential

Poor pricing information is harmful in any market. In a vertically connected health care system, it becomes more consequential because opacity can affect not only what a patient pays, but also which path through the system the patient takes.

Consider a patient seeking an advanced imaging service. The hospital may publish one estimate. The insurer may apply a deductible or coinsurance formula. A physician group may direct the patient to a facility that belongs to the same corporate network. A benefits administrator may classify one site as preferred. The patient may then receive a bill that bears little resemblance to the first number encountered.

At each stage, the patient is told that the next layer is responsible for the discrepancy. The hospital points to the insurer. The insurer points to the provider’s coding. The provider points to the complexity of the case. The patient is left with a system that is highly coordinated when revenue is being allocated and highly dispersed when accountability is being assigned.

This is the accountability gap created by layered integration. Ownership and influence are centralized, but explanations are distributed.

The same pattern appears in pharmaceuticals. A health plan may work with a pharmacy benefit manager, which negotiates with manufacturers and determines pharmacy networks. A specialty pharmacy may be owned by, or closely connected to, the broader enterprise. The arrangement may deliver operational benefits, but it also creates questions that cannot be answered by looking at a single transaction:

1. Who selected the product or site of care?
2. Who benefits when the patient uses a particular pharmacy or provider?
3. Which prices are being compared, and at what stage of the transaction?
4. Is the patient receiving the lowest available cost, or merely the price produced by the preferred channel?

The problem is not that every vertically integrated company is secretly overcharging. The problem is that the patient often lacks the information needed to distinguish efficiency from self dealing, coordination from steering, and legitimate clinical variation from commercial design.

This suggests a useful principle: the more decision points one organization controls, the stronger the obligation to make those decision points visible.

A company that merely sells a service can claim that its price reflects the service. A company that influences the insurance benefit, the referral, the pharmacy, the provider, and the reimbursement arrangement is shaping the entire route by which the price is created. It should therefore be judged not only by the price it posts, but by the clarity of the pathway that produces it.

From price transparency to pathway transparency

The usual debate asks whether hospitals and insurers should reveal their prices. That is necessary, but incomplete. The more useful goal is pathway transparency: the ability to follow a health care decision from recommendation to payment and identify the incentives and conditions at each stage.

Pathway transparency has four parts.

1. Identity transparency

Patients should be able to see who owns, controls, or financially benefits from each organization involved in their care. This does not require a legal treatise. A plain language label could state that a clinic, pharmacy, insurer, or benefits administrator belongs to the same corporate group as another participant in the transaction.

The purpose is not to stigmatize integration. It is to make relationships visible at the moment they may influence a choice.

2. Quote transparency

A quote should identify what it includes, what it excludes, and which assumptions generated it. For a childbirth estimate, that might include facility charges, professional fees, anesthesia, newborn care, common complications, and the patient’s insurance status. For an MRI, it should distinguish the technical component from the professional interpretation and explain whether contrast is included.

A number without a boundary is an invitation to misunderstanding.

3. Reproducibility transparency

A reasonable patient should receive materially similar information whether asking online, by phone, or through a representative. The method can differ, but the underlying estimate should not mutate simply because the question traveled through another channel.

This is where the matching and nonmatching estimates become especially revealing. Reproducibility is a practical test of whether a pricing system is real or merely performative. If two ordinary routes produce radically different answers, the organization has not yet converted its internal data into a usable public price.

4. Incentive transparency

Patients should be told when a recommendation is shaped by a preferred network, an affiliated pharmacy, a shared ownership structure, or a contractual arrangement. Again, this does not prove that the recommendation is wrong. It gives the patient the context needed to evaluate it.

These four forms of transparency turn a static disclosure requirement into a governance standard. The question changes from “Did the organization publish information?” to “Can a person understand how the system directed the decision and produced the bill?”

A practical mental model: follow the decision, not the invoice

Patients, employers, regulators, and journalists often begin with the invoice. That is understandable, but invoices are the final and least informative stage of the process. By then, the relevant decisions have already been made.

A better method is to follow the decision chain:

1. Who initiated the service or prescription?
2. Who selected the location, product, or channel?
3. Who set the conditions for access?
4. Who negotiated or administered the payment?
5. Who owns or benefits from the entities involved?
6. Which alternatives were available, and were they disclosed?

This method helps separate three kinds of variation that are often blended together.

Clinical variation arises because patients genuinely need different services. A complicated childbirth should not cost the same as an uncomplicated one. An MRI with contrast and an MRI without contrast are not identical products.

Market variation arises because different organizations negotiate different rates or operate at different costs. This variation may be legitimate, though it should be explainable.

Strategic variation arises when prices, referrals, networks, or information are arranged to steer people toward a profitable channel. Strategic variation is not necessarily visible in the final bill. It often appears in the path that led to the bill.

The most important policy and consumer tools should therefore test not only whether prices vary, but why they vary and who had the power to create the variation.

Key Takeaways

1. Treat a price estimate as a claim that must be tested, not a fact that must be accepted. Ask what services, fees, assumptions, and insurance conditions are included.

2. Request the same estimate through more than one channel. Meaningful differences between an online quote and a phone quote are evidence that the pricing process needs clarification.

3. Map the ownership and incentive structure behind a recommendation. Ask whether the referring clinic, preferred pharmacy, insurer, and facility share ownership or financial relationships.

4. Separate clinical, market, and strategic variation. A higher price may reflect a more complex service, a different negotiated rate, or a designed incentive. Do not treat these explanations as interchangeable.

5. Demand pathway transparency from institutions. The best disclosure shows not only the price, but how the patient arrived at that price and what alternatives were available.

The central challenge in health care is not simply that prices are high. It is that the system can be simultaneously sophisticated enough to coordinate billions of dollars and too incoherent to answer a patient’s basic question consistently.

Vertical integration may make health care companies more capable. It does not automatically make health care more accountable. In fact, the greater the concentration of decision making, the more dangerous it is to mistake a visible number for genuine transparency.

A truly transparent system would not force patients to become detectives. It would show the route from recommendation to treatment to payment, identify the relationships shaping that route, and produce estimates that remain stable when asked in ordinary ways.

The future of health care transparency should therefore be judged by a different standard. Do not ask only whether the data is posted. Ask whether a patient can use it to understand who made the decision, who benefits from it, what alternatives exist, and what the final cost is likely to be.

The most revealing price in health care may not be the one printed on the bill. It may be the price of navigating a system whose institutions are integrated enough to coordinate with one another, but not transparent enough to explain themselves.